- Home
- SBFG vs CRBP Comparison
SBFG vs CRBP Comparison
Compare SBFG & CRBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SBFG | CRBP |
|---|---|---|
| Founded | 1983 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 182.2M | 190.3M |
| IPO Year | 2014 | 2014 |
Fundamental Metrics
Financial Performance| Metric | SBFG | CRBP |
|---|---|---|
| Price | $28.89 | $7.55 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $45.50 |
| AVG Volume (30 Days) | 11.3K | ★ 967.5K |
| Earning Date | 04-23-2026 | 05-08-2026 |
| Dividend Yield | ★ 2.98% | N/A |
| EPS Growth | ★ 27.33 | N/A |
| EPS | ★ 1.41 | N/A |
| Revenue | N/A | ★ $4,822,272.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $116.00 |
| P/E Ratio | $20.86 | ★ N/A |
| Revenue Growth | N/A | ★ 97.62 |
| 52 Week Low | $18.16 | $6.33 |
| 52 Week High | $30.07 | $20.56 |
Technical Indicators
Market Signals| Indicator | SBFG | CRBP |
|---|---|---|
| Relative Strength Index (RSI) | 61.49 | 32.94 |
| Support Level | $28.31 | N/A |
| Resistance Level | $30.07 | $8.54 |
| Average True Range (ATR) | 0.90 | 0.80 |
| MACD | -0.01 | -0.39 |
| Stochastic Oscillator | 78.11 | 24.36 |
Price Performance
Historical ComparisonAbout SBFG SB Financial Group Inc.
SB Financial Group Inc that provides a range of community banking services, including commercial and consumer lending, personal and business banking, treasury management and merchant services, personal wealth management and brokerage services, and other financial services to individuals, businesses, and municipalities. It operates in a single segment, which is Banking.
About CRBP Corbus Pharmaceuticals Holdings Inc.
Corbus Pharmaceuticals Holdings Inc is a clinical stage company focused on new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing inventive scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.